Rexin-G
AXP000210.1 · Viral vector gene therapy
- Platform
- pathotropic retroviral vector (MoMLV-based, collagen-targeted envelope)
- Targets
- CCNG1
- Originator
- Epeius Biotechnologies (Erlinda M. Gordon, Frederick L. Hall)
- Sponsor
- Delta Next-Gen / Aveni Foundation
Names
| Name | Type | Source |
|---|---|---|
| Rexin-G | preferred name, code | curator, ncit |
| Mx-dnG1 | code | ncit |
| DeltaRex-G | synonym | ncit |
| Retrovector Encoding Mutant Anti-Cyclin G1 | synonym | ncit |
Virus
- Role
- In vivo gene transfer
- Family
- Retroviridae
- Virus
- murine leukemia virus (NCBI Taxonomy 11786)
- Strain
- MoMLV-based pathotropic vector
- Replication
- non replicating
- Modifications
- replication-incompetent MoMLV vector; von Willebrand factor-derived collagen-binding sequence inserted in the envelope protein for targeting to exposed collagen in tumour stroma
- Transgenes
- CCNG1 (N-terminal-deletion dominant-negative cyclin G1)
- Route
- intravenous, intra arterial
- Source
- evidence
Cross-references
- NCI Thesaurus
- C49082
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| other | PH | 2007 | conditional | Rexin-G | Accelerated approval for the treatment of all solid tumours | source |
Clinical trials (6)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04378244 | CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 | Withdrawn | Phase 1/2 | 2022-12-12 | 2023-12-12 | 0 | Acute Respiratory Distress Syndrome; COVID-19; Cytokine Storm |
| NCT00572130 | Phase II Study of Intravenous Rexin-G in Osteosarcoma | Completed | Phase 2 | 2007-12 | 2010-07 | 22 | Osteosarcoma |
| NCT00505713 | Safety and Efficacy Study Using Rexin-G for Sarcoma | Completed | Phase 1/2 | 2007-07 | 2010-07 | 36 | Sarcoma |
| NCT00505271 | Safety and Efficacy Study Using Rexin-G for Breast Cancer | Completed | Phase 1/2 | 2007-07 | 2010-07 | 20 | Breast Cancer |
| NCT00504998 | Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer | Completed | Phase 1/2 | 2007-07 | 2010-07 | 20 | Pancreatic Cancer |
| NCT00121745 | Evaluation of Safety of Rexin-G Gene Transfer for Advanced Pancreatic Cancer | Terminated | Phase 1 | 2005-07 | 12 | Pancreatic Cancer |
Unconfirmed matches (1)
Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions | Matched by |
|---|---|---|---|---|---|---|---|---|
| NCT00035919 | Safety and Efficacy of Targeted Gene Transfer in Colorectal Cancer Metastatic to Liver | Withdrawn | Phase 1/2 | 2002-11 | 0 | Colorectal Neoplasms | name in intervention: Mx-dnG1 |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 19826403 | Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer. | Molecular therapy : the journal of the American Society of Gene Therapy | 2010 | name in title: Rexin-G |
| PMID 20428757 | Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent. | International journal of oncology | 2010 | name in title: Rexin-G |
| PMID 20811660 | Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene delivery. | Oncology reports | 2010 | name in abstract: Rexin-G |
| PMID 19532136 | Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma. | Molecular therapy : the journal of the American Society of Gene Therapy | 2009 | name in title: Rexin-G |
| PMID 18388964 | Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. | Molecular therapy : the journal of the American Society of Gene Therapy | 2008 | name in title: Rexin-G |
| PMID 17487349 | Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. | International journal of oncology | 2007 | name in abstract: Rexin-G |
| PMID 14654955 | First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. | International journal of oncology | 2004 | name in title: Rexin-G |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40227707 | Gene and Cell Therapy for Sarcomas: A Review. | Cancers | 2025 | name in abstract: Rexin-G |
| PMID 38925853 | Proceedings of the Think Tank for Osteosarcoma Medical Advisory Board. | Anticancer research | 2024 | name in abstract: DeltaRex-G |
| PMID 39359418 | DeltaRex-G, tumor targeted retrovector encoding a CCNG1 inhibitor, for CAR-T cell therapy induced cytokine release syndrome. | Frontiers in molecular medicine | 2024 | name in title: DeltaRex-G |
| PMID 37065938 | Oncolytic virus-based suicide gene therapy for cancer treatment: a perspective of the clinical trials conducted at Henry Ford Health. | Translational medicine communications | 2023 | name in abstract: Rexin-G |
| PMID 37247916 | Early-stage CCNG1+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a CCNG1 Inhibitor. | Anticancer research | 2023 | name in title: DeltaRex-G |
| PMID 39086675 | Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast. | Frontiers in molecular medicine | 2023 | name in title: DeltaRex-G |
| PMID 39086973 | Three year results of Blessed: Expanded access for DeltaRex-G for an intermediate size population with advanced pancreatic cancer and sarcoma (NCT04091295) and individual patient use of DeltaRex-G for solid malignancies (IND# 19130). | Frontiers in molecular medicine | 2022 | name in title: DeltaRex-G |
| PMID 34277005 | Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review. | Molecular and clinical oncology | 2021 | name in title: DeltaRex-G |
| PMID 30705966 | A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. | Molecular therapy oncolytics | 2019 | name in title: Rexin-G |
| PMID 28588778 | Rexin-G®, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report. | Molecular and clinical oncology | 2017 | name in title: Rexin-G |
| PMID 21519259 | Phase 1 clinical trials for sarcomas: the cutting edge. | Current opinion in oncology | 2011 | name in abstract: Rexin-G |
| PMID 20384524 | Rexin-G, a targeted genetic medicine for cancer. | Expert opinion on biological therapy | 2010 | name in title: Rexin-G |
| PMID 20664824 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2010 | name in abstract: Mx-dnG1 |
| PMID 19578735 | The 'timely' development of Rexin-G: first targeted injectable gene vector (review). | International journal of oncology | 2009 | name in title: Rexin-G |
| PMID 19798455 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2009 | name in abstract: Mx-dnG1 |
| PMID 18813779 | Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. | International journal of oncology | 2008 | name in abstract: Rexin-G |
| PMID 17016635 | Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience. | International journal of oncology | 2006 | name in title: Rexin-G |
| PMID 15844625 | Technology evaluation: Rexin-G, Epeius Biotechnologies. | Current opinion in molecular therapeutics | 2005 | name in title: Rexin-G |
| PMID 15870914 | Nanotechnology blooms, at last (Review). | Oncology reports | 2005 | name in abstract: Rexin-G |
| PMID 11177556 | Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. | Human gene therapy | 2001 | name in abstract: Mx-dnG1 |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01FD003071 | Phase I Clinical Trial Using Rexin-G for Pancreatic Can* | EPEIUS BIOTECHNOLOGIES CORPORATION | HALL, FREDERICK L | 2006–2007 | name in title: Rexin-G |
Notes
Replication-incompetent MoMLV-based vector whose envelope carries a von Willebrand factor-derived collagen-binding peptide, delivering a cytocidal N-terminal-deletion (dominant-negative) human cyclin G1 construct; given by intravenous infusion. Renamed DeltaRex-G. Reported as approved for all solid tumours in the Philippines (accelerated approval, 2007); the approval year comes from secondary sources, not an agency record. Not an oncolytic virus: the vector does not replicate.
How to cite
Rexin-G (AXP000210.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000210.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.